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chemotherapy
Catherine M. Clavel, Patrycja Nowak-Sliwinska, Emilia Păunescu and Paul J. Dyson*
Hyperthermia is currently being explored as an adjuvant treatment to conventional therapies with chemo-
therapeutic agents based on thermoresponsive macromolecules. Although the concept of hyperthermia
has existed for many years it has yet to become routinely used in the clinical management of cancer. The
development of small thermoresponsive molecules could help to change this paradigm. Temperature-
sensitive compounds have recently been developed by covalently modifying drug and drug-like molecules
with thermomorphic perfluorinated appendages. Lead thermoresponsive compounds have been validated
in a pre-clinical model, displaying high tumor growth inhibition, with strong synergies observed between
hyperthermia and the thermomorphic compounds.
Introduction
Surgical removal of solid tumors often fails to result in total
remission and is therefore accompanied by chemotherapy,
radiotherapy or a combination of the two.1,2 The lack of selec-
tivity of chemotherapy leads to multiple side-effects, such as
nephrotoxicity, blood disorders, fatigue, hair loss, nausea and
vomiting.3 Therefore, alternative methods that combine che-
motherapy with other treatment strategies have been explored
in order to improve treatment selectivity, reduce recurrence
and improve the quality of life of patients.
One approach that may achieve these goals is to combine
chemotherapy with hyperthermia (the application of heat).
Hyperthermia, delivered at a continued or fractionated dose,
can sensitize tumors to chemotherapy, radiotherapy, immu-
notherapy and immune-based strategies.4 The enhanced sen-
sitivity of tumors to heat and the potential of hyperthermia
in cancer treatment has been recognized for many years.5,6
However, the successful application of local hyperthermia
(where heat is applied only at the tumor site) in combination
with chemotherapeutics, has led to renewed interest in the
approach.7 Recent years have witnessed substantial technical
improvements in selectively heating superficial and deep-
located tumors and the development of thermosensitive
macromolecular drug delivery vehicles.8
Hyperthermia sensitizes cells to therapeutic agents and
activates drug release from thermoresponsive nanocarriers
(usually below 43 °C, referred to as mild hyperthermia) or, at
higher temperatures, directly inducing necrosis (above 43 °C,
referred to as thermal ablation).9 Importantly, cancer tissue
is more thermosensitive than normal tissue between 42 °C
and 45 °C,10 with a proportional relationship between cell
death and the exposure time/temperature.11 There are various
mechanisms by which local hyperthermia affects a cell lead-
ing to an enhanced antitumor response, see Fig. 1.12 Hyper-
thermia disrupts cell membrane function, enhances perme-
ability and modifies the fluidity, stability and shape of the
membrane, impeding transmembrane transport proteins and
cell surface receptors.13,14 Heat transfer away from tumor tis-
sue depends on the rate and volume of tumor perfusion,15
and this process is usually less efficient in malignant tissue
compared to healthy tissues,16,17 enhancing the selectivity of
hyperthermia.18
Hyperthermia can effect cells in many different ways.19 It
is known that heat can alter the structure of endogenous
molecules such as lipids, nucleotides and proteins. Although
the effects on lipids are reversible, the effects on DNA, i.e.
the generation of double strand breaks, can be substantial
and less easily reversed. However, the largest effects of hyper-
thermia are believed to be on proteins as they undergo dena-
turation and aggregation at temperatures >39 °C. This leads
to inhibition of many cellular processes such as cell cycle
arrest, inactivation of protein synthesis and inhibition of
DNA synthesis and repair, resulting in inhibition of prolifera-
tion and cell death.20–22 Other important cellular changes
induced by hyperthermia include the destruction of the cyto-
skeleton, making cellular motility difficult, and enhanced
degradation of proteins through the proteasome and lyso-
somal pathways. In addition, changes in cellular metabolism
resulting in decreased availability of ATP and enhanced pro-
duction of reactive oxygen species (ROS) have been
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described.23,24 All these cellular changes ultimately lead to
the loss of cell membrane integrity.
While these changes occur at the cellular level in all cells
in the heated area, at a higher level vascular disruption also
takes place, leading to vascular dysfunction and tissue eradi-
cation.25,26 However, as the vasculature is perfused the extent
of hyperthermia is more moderate in the vessels, but never-
theless may result in better tumor perfusion. Such increased
perfusion facilitates increased trafficking of immune cells
including T cells and dendritic cells.27,28 The above-
mentioned mechanisms may be differently balanced in spe-
cific tumor types as well as from patient to patient. Since
heating tumors activates an immune response, at least in
part by the upregulation of heat shock proteins, and since
activity of some chemotherapeutics depend on heat shock
proteins,29 it may suggest that these treatment strategies may
act synergistically.
Combining small-molecule anticancer
drugs with hyperthermia
Combining hyperthermia with chemotherapy frequently gives
contrasting results in vitro and in vivo due to the ways in
which hyperthermia effects the tumor microenvironment (see
above). Drug exposure to cells remains relatively stable
in vitro whereas in malignant tissue it is affected by the
changes of the tumor blood flow induced by hyperthermia.30
Nevertheless, early studies demonstrated that alkylating
agents such as methyl methanesulfonate (Fig. 2) exhibit supe-
rior effects in conjunction with hyperthermia at 41–42
°C,31,32 attributed to higher levels of DNA single strand
breaks and reduced DNA repair.33 In other studies comparing
melphalan, cisplatin and cyclophosphamide in combination
with hyperthermia (41 °C) only cyclophosphamide resulted in
an improved therapeutic response.34,35
Cisplatin was found to reduce tumor growth more effi-
ciently in mouse mammary and rat glioma tumors when
applied simultaneously with hyperthermia,36 although renal
damage in rats resulting from the combination treatment
were heightened.37 No enhancements in the reduction of
tumor growth were detected for the antimetabolites,
vinblastine and etoposide (Fig. 3) when combined with
Fig. 1 Different mechanisms of antitumor activity induced by local hyperthermia of tumors: loss of membrane integrity, upregulation of heat
shock proteins, activation of immune cells, necrotic cell death and vessel destruction.
Fig. 2 Structures of the alkylating agents methyl methanesulfonate (a), melphalan (b), cyclophosphamide (c), cisplatin (d) and carboplatin (e).
Fig. 3 Structures of the antimetabolites vinblastine (a) and etoposide (b).
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hyperthermia, possibly due to drug instability at the elevated
temperatures.38
To improve treatment protocols and reduce the side
effects of hyperthermia, heating can be applied regionally or
only locally and, furthermore, by careful timing of the treat-
ment, with respect to drug administration, additional
enhancements are possible. Indeed, the sequence and timing
of chemotherapy and hyperthermia are critical for enhanced
tumor reduction and it was shown for several drugs (cis-
platin, melphalan and carboplatin, Fig. 2) that simultaneous
administration of drug and heat is optimal.39,40 As men-
tioned above, hyperthermia can modify the tolerance of a
tumor to chemotherapy leading to thermotolerance, an adap-
tive survival response, induced by heat preconditioning,
whereby cells become resistant to a subsequent lethal insult.
Therefore, the most advantageous treatment schedules
involve administration of a chemotherapeutic before applica-
tion of hyperthermia,41 or the simultaneous application of
the two regimens.39,40 For cisplatin, it was shown that the
concentration of the drug in the tumor is higher when
injected prior to hyperthermia, presumably because hyper-
thermia induces vasodilatation following administration
leading to an initial enhancement of drug retention in the
tumor microenvironment with subsequent stabilization of
tumor blood flow enhancing entrapment of the drug.42
Continuously circulating a heated solution containing che-
motherapeutic agents inside the peritoneal cavity, a tech-
nique known as hyperthermic intraperitoneal chemotherapy,
allows fast drug delivery to the gastric region. This approach
was subsequently applied in clinical trials with cytoreductive
surgery in gastric and ovarian carcinomas, in combination
with cisplatin (Fig. 2) or mitomycin C (Fig. 4), in the treat-
ment of malignant mesothelioma in combination with mito-
mycin C in phase II clinical trials,43–45 and in a phase III
study on colorectal carcinoma employing 5-fluorouracil and
leucovorin (Fig. 4).46–48
Promising results were obtained with gemcitabine (Fig. 4)
combined with cisplatin and regional hyperthermia as a
second-line treatment for gemcitabine-resistant advanced
and metastatic tumors.49 Moreover, patients with cervical
cancer that did not respond to radiotherapy were adminis-
tered weekly with cisplatin and regional hyperthermia in a
phase II study with a response rate of 50% observed for
hyperthermia-chemotherapy treated patients compared to
only 15% for patients treated with chemotherapy alone.50,51
In phase II clinical studies doxorubicin, ifosfamide and
etoposide52 or etoposide and ifosfamide (Fig. 5)53 were
applied together with regional hyperthermia and shown to
improve local control in high-risk, soft-tissue sarcoma com-
pared to chemotherapy alone (a four year overall survival of
59% was achieved with the latter combination compared to
40% for chemotherapy alone). These promising results led to
large and randomized phase III clinical trials with the first
completed study showing moderate toxicity including skin
burns, but with the response rate more than doubling under
hyperthermia (28.8 vs. 12.7%), and an increased local
progression-free survival at 2 years (76% vs. 61%).7 Another
study investigated the chemotherapy combination compris-
ing ifosfamide, carboplatin and etoposide as a second-line
treatment with hyperthermia in soft-tissue sarcoma refractory
with an objective response rate of 20%.54 In phase III clinical
trials hyperthermia led to significant clinical benefits using
regional hyperthermia for superficial and deep local
advanced tumors such as high-risk soft-tissue sarcoma.
Macromolecular thermoresponsive
systems
The application of small molecules applied with hyperther-
mia indicates the considerable potential of the approach in
cancer therapy. However, the molecules described above were
Fig. 4 Structures of leucovorin (a) mitomycin C (b), 5-fluorouracil (c) and gemcitabine (d).
Fig. 5 Structures of doxorubicin (a), ifosfamide (b) and temozolomide (c).
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not originally designed to be applied with hyperthermia, indi-
cating that more effective compounds could be developed.
Initial attempts to adapt compounds to hyperthermia were
based on the encapsulation of established drugs in liposomes
with temperature-dependent drug release characteristics.
These macromolecular systems have the added advantage
that liposomes also preferentially accumulate in solid tumors
due to the enhanced permeation and retention of
macromolecules.55
Notably, liposomal formulations of doxorubicin (Fig. 5)
have been extensively studied in thermotherapy.56,57 A drug
delivery system that shows considerable promise is based on
a low temperature sensitive liposome containing doxorubicin,
termed ThermoDox®, which releases the drug in a few sec-
onds at 42 °C.58,59 The heat-sensitive liposome changes struc-
ture as a function of temperature and, as the temperature
increases, pores in the liposome are created which release
doxorubicin directly into the heated tumor.60 ThermoDox® is
currently in phase III clinical trials in combination with
hyperthermia for the treatment of hepatocellular carcinoma.
However, a significant proportion of the encapsulated doxo-
rubicin in ThermoDox® is lost following intravenous admin-
istration61,62 and, consequently, alternative drug delivery sys-
tems have been developed. A cationic thermoresponsive
liposomal system incorporating doxorubicin and ammonium
bicarbonate operates via an alternative mechanism. At the
heated tumor site CO2 bubbles are produced that induce the
release of the doxorubicin.57 In another variant the doxorubi-
cin is coordinated to manganese ions, which enhances
encapsulation without impacting on the temperature-
triggered release and pharmacokinetics of the drug delivery
system.61 Cisplatin encapsulated in preformed thermo-
responsive cholesterol-containing liposomes is stable at 37
°C (<5% released), whereas >95% is released within 5
minutes at 42 °C.63 Nanoparticles have also been explored as
thermoresponsive drug nanocarriers, including iron oxide
magnetic nanoparticles,64 acid-capped poly(lactic-co-glycolic
acid) nanoparticles,65 silica-coated magnetic lanthanum–
strontium manganite nanoparticles66 or other surface-
modified nanoparticles,67,68 all incorporating doxorubicin as
the active drug molecule.
An advantage of certain macromolecular drug delivery sys-
tems is that they can traverse the blood–brain barrier.69 For
example, a liposomal doxorubicin formulation (Caelyx®) able
to cross the blood–brain barrier was found to accumulate in
glioblastoma and brain metastases.70 A multimodality treat-
ment comprising radiotherapy, hyperthermia and chemother-
apy, i.e. temozolomide (Fig. 5), with added Caelyx® for resis-
tant cases, led to enhanced survival rates in a glioblastoma
clinical trial.71 More than 50% patients remained alive after
26 months whereas the median survival following surgery is
usually <4 months, which is only slightly improved with
radiotherapy.72,73
Heat seeking drug-loaded polypeptide nanoparticles based
on a thermally responsive elastin-like polypeptide conjugated
to multiple copies of doxorubicin have been reported
recently.74 These nanoparticles were able to target tumors
that were externally heated to 42 °C.75 Thermal cycling
(heating and cooling) of the tumors following injection of the
thermally responsive nanoparticles results in a significant
enhancement of doxorubicin accumulation in the tumor.74,76
New small-molecule
thermoresponsive compounds
Despite the development of macromolecular drug formula-
tions for thermotherapy, notably liposomal formulations,
small-molecule drugs not designed for use in combination
with hyperthermia continue to be evaluated in clinical trials.
There are clinical advantages in using low molecular weight
thermosensitive drugs that are selectively activated at the
tumor site by the application of hyperthermia. In this context
many highly fluorinated compounds have excellent
thermomorphic properties77–79 and fluorine compounds
already play an important role in medicinal chemistry.80–82
Numerous anticancer drugs such as 5-fluorouracil (Fig. 4),83
rosuvastatin and fluticasone84 and torcetapib85 contain one
or more fluorine atoms (Fig. 6). Perfluorinated systems have
also been investigated as drug delivery systems and were
shown to exhibit prolonged circulation times in the blood.86
Drug absorption and biodistribution rely mainly on the lipo-
philicity/hydrophilicity of the system and fluorine-containing
compounds have unique properties in this regard, with
diverging lipophilic and hydrophobic characteristics
depending on the fluorine atom content.
Perfluorinated solvents undergo temperature-dependent
miscibility with organic solvents and water87,88 and the solu-
bility of certain fluorinated compounds varies considerably
as a function of temperature.89,90 Moreover, certain fluoro-
polymers exhibit biocompatible characteristics and have been
Fig. 6 Structures of the fluorine-containing drugs rosuvastatin (a), fluticasone (b) and torcetrapib (c).
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evaluated in various biomedical applications.91,92 Based on
these observations, the first small-molecule anticancer com-
pounds containing perfluorinated chains attached via a phos-
phine ligand to bioactive rutheniumĲII)–arene moieties were
designed and evaluated in vitro (Fig. 7, PTA = 1,3,5-triaza-7-
phosphatricycloĳ3.3.1.1]decane).93 The solubility of the com-
pounds at 37 °C was low and in some cases increased consid-
erably at 42 °C. Some of the compounds were found to be
strongly cytotoxic to human ovarian A2780 and A2780cisR
cancer cell lines (the latter having acquired resistance to cis-
platin) under normal conditions, i.e. at 37 °C. Including a 42
°C heating cycle for 2 hours during the incubation period
increased their cytotoxicity.
Although non-fluorinated rutheniumĲII)–arene compounds
related to those shown in Fig. 7 show encouraging in vivo
properties,94–100 as yet, none have progressed to clinical tri-
als. Consequently, the widely explored and clinically
approved alkylating agent, chlorambucil, p-(ClĲCH2)2)2N-
C6H4-(CH2)3-CO2H, was derivatized with perfluorinated
chains via an ester linkage in order to better assess the
thermoresponsive potential of the compound. These
chlorambucil derivatives were shown to exhibit significant
differences when applied to cancer cells under normal con-
ditions and under mild hyperthermia at 42 °C.101 Notably,
chlorambucil modified with a long (C10) perfluorous chain,
i.e. p-(ClĲCH2)2)2N-C6H4-(CH2)3-CO2-(CH2)2ĲCF2)9CF3 (Fig. 8),
is only cytotoxic following a 2 hour hyperthermia signal. In
the various cancer cell lines tested the compound is consis-
tently more cytotoxic following hyperthermia. For example, at
37 °C in the A2780 and A2780cisR cell lines the compound is
inactive at the maximum concentration that could be tested
(200 μM), whereas with the inclusion of a 2 hour period at 42
°C during the 72 hour incubation period IC50 values of 37
and 40 μM, respectively, were obtained. In the same cell lines
chlorambucil was less cytotoxic when applied in combination
with hyperthermia, and analogues in which the fluorous
chain is replaced by a hydrocarbon chain do not show clear
thermoresponsive behavior. Note that the logP values of the
chlorambucil derivatives with fluorous chains are signifi-
cantly higher (ca. 9–12) than those with alkyl chains (ca. 6).
In the case of the longest chain derivatives (both fluorous
and alkyl chains) a significant increase in solubility in water
was observed as the temperature changes from 37 to 43 °C.101
The thermoresponsive properties of p-(ClĲCH2)2)2N-
C6H4-(CH2)3-CO2-(CH2)2ĲCF2)9CF3 was also demonstrated
in vivo using a mouse model bearing the human LS-174 T
tumor.102 At a dose of 12.5 mg kg−1, administered a total of
three times every four days, a reduction in tumor growth of
59% is observed under normal conditions, i.e. without hyper-
thermia. When combined with a 30 minute hyperthermia sig-
nal a few minutes after injection tumor growth inhibition
increases to 79%.
The mechanism of tumor cell death induced by the com-
pound appears to be the same as that of chlorambucil itself
and involves DNA damage. However, the mechanism of ther-
mal activation remains unclear, although it would appear to
involve increased solubility at the heated tumor site with con-
comitant cleavage of the fluorous chain at the ester linker.
Compounds in which the fluorous chain is covalently linked
to the drug via non-cleavable groups do not appear to be
endowed with such extensive thermoresponsive activity. Hence,
the original thermoresponsive ruthenium complexes mentioned
above were redesigned with the fluorous chain tethered to a
pyridine ligand via an ester linkage (Fig. 8).103 These ruthenium
Fig. 7 RutheniumĲII)–arene complexes with fluorinated phosphines that modest exhibit thermoresponsive behavior; [RuĲη6-p-
cymene)ĲPTA)ClĲPPh2Ĳp-C6H4ĲCH2)2ĲCF2)7CF3))]ĳBF4] (a) and [RuĲη
6-p-phenyl-2-butanol)ĲPTA)ClĲPPh2Ĳp-C6H4ĲCH2)2ĲCF2)7CF3))]ĳBF4] (b). The counter
anion is not shown.
Fig. 8 Structures of chlorambucil (a), p-(ClĲCH2)2)2N-C6H4-(CH2)3-
CO2-(CH2)2ĲCF2)9CF3 (b) and [RuĲη
6-p-cymene)Cl2ĲC5H4N-3-(CH2)2-
CO2-(CH2)2ĲCF2)9CF3)] (c).
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compounds display a remarkable selectivity to cancer cells
in vitro when used in combination with a 2 hour hyperther-
mia treatment of 41 °C. For the most effective compound,
[RuĲη6-p-cymene)Cl2ĲC5H4N-3-(CH2)2-CO2-(CH2)2ĲCF2)9CF3)],
cytotoxicity was not observed at concentrations <500 μM
under normal conditions whereas with the inclusion of a 2
hour heating period at 42 °C during the 72 hour incubation
resulted in IC50 values as low as 5 μM (in MCF-7 human
breast cancer cells), i.e. two orders of magnitude greater inhi-
bition of cell growth for the combination with hyperthermia.
Notably, in non-cancerous human endothelial HEK-293 cells
hyperthermia did not lead to such a large increase in cell
growth inhibition with an observed IC50 value of 132 μM.
[RuĲη6-p-cymene)Cl2ĲC5H4N-3-(CH2)2-CO2-(CH2)2ĲCF2)9CF3)]
was evaluated in vivo in the same model used to test the
chlorambucil derivative at an equivalent dose and adminis-
tration/heating regime.102 Tumor growth inhibition of 66%
was observed under normal conditions, which increases to
90% when combined with hyperthermia. Based on histo-
chemical analysis tumor growth inhibition was attributed to
the inhibition of cell proliferation and, in part, to necrosis,
the latter feature having been observed in other combination
studies employing hyperthermia.104 The toxicity of the com-
pound appears to be largely limited to the heated tumor
region as weight loss and other side effects were not
observed. Moreover, the ruthenium distribution in the vital
organs is not aggravated by the heat treatment process and
the distribution of ruthenium is similar to other ruthenium
compounds that are not cytotoxic.102,105,106 It has also been
suggested that the selective delivery of the compound to the
heat tumor site could also be due to temperature-dependent
interactions with certain serum proteins.107
Concluding remarks
Randomized clinical trials have demonstrated overall patient
survival prolongation with hyperthermia-drug treatment regi-
mens applied to a wide range of malignancies. However, in
order to make a local hyperthermia a more powerful cancer
treatment strategy all possible factors of the treatment must
be optimized. This optimization process is not trivial due to
the difficulties associated with maintaining the optimum
intra-tumor temperature,108,109 hyperthermia-induced drug
targeting110 and selective drug activation by heat.
Fig. 9 Proposed generic mechanism of action of thermoresponsive fluorous-tagged drugs.
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Nevertheless, multiple studies have shown that hyperthermia
complements chemosensitization and the mechanism of
action of this dual-therapy appears to be dependent on the
particular mechanism of each chemotherapeutic compound.
Further improvements of this treatment strategy will
undoubtedly involve the development of more efficient heat-
responsive drugs. The strategy reported herein, i.e. based on
modifying clinically approved drugs or putative drug-like
molecules with fluorous chains conjugated via ester linkages,
certainly holds promise. A tentative, generic mechanism
concerning drug delivery and heat activation is shown in Fig. 9
and, while the approach has thus far only been demonstrated
on a limited number of compounds, it is not unreasonable to
assume that it can be applied to almost any bioactive (antican-
cer) molecule. However, further validation of this approach is
still needed as fluorous-tagged compounds also display relevant
therapeutic properties under normal conditions111–113 and to
determine whether it has advantages over the well-established
use of thermoresponsive macromolecular drug delivery sys-
tems, some of which are progressing through clinical trials.
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